Frontiers in Immunology (Sep 2023)
Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation
- Guo-Qing Tang,
- Yalan Tang,
- Ketki Dhamnaskar,
- Michelle D. Hoarty,
- Rohit Vyasamneni,
- Douangsone D. Vadysirisack,
- Zhong Ma,
- Nanqun Zhu,
- Jian-Guo Wang,
- Charlie Bu,
- Bestine Cong,
- Elizabeth Palmer,
- Petra W. Duda,
- Camil Sayegh,
- Alonso Ricardo
Affiliations
- Guo-Qing Tang
- UCB Pharma, Cambridge, MA, United States
- Yalan Tang
- UCB Pharma, Cambridge, MA, United States
- Ketki Dhamnaskar
- Ra Pharmaceuticals, Cambridge, MA, United States
- Michelle D. Hoarty
- UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States
- Rohit Vyasamneni
- Ra Pharmaceuticals, Cambridge, MA, United States
- Douangsone D. Vadysirisack
- UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States
- Zhong Ma
- UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States
- Nanqun Zhu
- UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States
- Jian-Guo Wang
- UCB Pharma, Cambridge, MA, United States
- Charlie Bu
- UCB Pharma, Cambridge, MA, United States
- Bestine Cong
- UCB Pharma, Cambridge, MA, United States
- Elizabeth Palmer
- UCB Pharma, Cambridge, MA, United States
- Petra W. Duda
- UCB Pharma, Cambridge, MA, United States
- Camil Sayegh
- UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States
- Alonso Ricardo
- Ra Pharmaceuticals, Cambridge, MA, United States
- DOI
- https://doi.org/10.3389/fimmu.2023.1282155
- Journal volume & issue
-
Vol. 14
Abstract
No abstracts available.Keywords
